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Please refer to the article on pages 367–368 of this issue to view
the questions to which these answers refer.
1. After 21 days of anti-tuberculosis (TB) treatment, the
patient agreed to an open lung biopsy, and a 2.5 cm lung tissue
sample was duly obtained. The sample contained several yellow
nodules 1–3 mm in diameter; intervening tissue was relatively
normal. Examination of frozen sections revealed granulomatous
inflammation centered entirely around terminal bronchioles
and partially obliterated bronchiolar lumina (Figure 2). Neither
acid-fast bacilli nor specific granulomas were observed. These
findings were consistent with bronchiolitis obliterans organiz-
ing pneumonia (BOOP).
Following diagnosis, treatment with corticosteroids (predni-
sone 1 mg/kg/day) was added to anti-TB drugs. Two weeks
later, the patient was asymptomatic and chest X-rays were
normal (Figure 1b). Anti-TB treatment was continued for
18 months, but ethambutol was stopped after the first 2 months.
Prednisone was given for 2 weeks, and thereafter gradually
withdrawn. Today, the patient remains asymptomatic.
BOOP, also called cryptogenic pneumonia, is a recognized
clinicopathologic entity characterized by the presence of myx-
omatous connective tissue plugs in the bronchiolar lumen,
extending into alveoli [1]. Diagnosis is largely histologic, and
an open lung biopsy is often considered necessary. The disease
may be idiopathic or may be associated with a number of lung
conditions, including lung allograft rejection and pulmonary
infections [2]. The term ‘bronchiolitis’ covers two distinct
clinicopathologic entities, both of which affect the small air-
ways: (1) constrictive bronchiolitis [1]; and (2) BOOP or
cryptogenic pneumonia [3]. The main characteristics are pre-
sented in Table 1.
BOOP did not become a fully recognized entity until it was
described by Epler in 1985 [4]. Histologically, the most relevant
feature is the presence of granulated tissue plugs in bronchiolar
lumina, extending into alveoli, accompanied by fibrosis and
predominantly mixed lymphoplasmocellular interstitial inflam-
mation [1,5].
2. BOOP may present as a primary disease of unknown
etiology, or may be secondary to: collagen vascular diseases such
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Figure 1b Chest X-ray after corticosteroid treatment.
as rheumatoid arthritis; inhalation of poisonous gases; drugs
such as bleomycin, cephalosporin, busulfan or cocaine; irradia-
tion; or infection [1,2]. The main microorganisms associated
with this entity are listed in Table 2.
Although BOOP has been associated with numerous micro-
organisms, a bibliographic search through MEDLINE from
1992 to August 2000 revealed no report of association with
Mycobacterium tuberculosis.
The patient described here was an immunocompromised
host from a country where TB is endemic. He may have had
previous contact with M. tuberculosis prior to transplant, and
immunosuppressive treatment may have favored the develop-
ment of TB. The relationship between TB and bronchiolitis has
not been fully confirmed, and the etiology of BOOP in this
patient may involve some degree of interplay between the
infectious agent (M. tuberculosis) and the transplant; however,
Table 1 Characteristics enabling differentiation between constrictive bronchiolitis and bronchiolitis obliterans organizing pneumonia
Constrictive bronchiolitis
Bronchiolitis obliterans
organizing pneumonia
Histology Concentric fibrosis of
bronchioles that may
completely obliterate
the bronchiolar
lumen
Bronchiolar interluminal
granulation tissue plugs,
extending into the
alveoli
Radiographic findings Normal or hyperinflated lung Diffuse or focal infiltrate
Lung function Obstructive Restrictive or mixed
obstructive^restrictive
Evolution Pulmonary fibrosis Favorable
Figure 2 Histologic examination of lung biopsy.
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the absence of graft rejection, coupled with histologic and
microbiological findings, strongly suggests that BOOP was
due to bronchial spread from initial TB.
3. Little information is available regarding TB in transplant
patients, since few cases have been reported to date. According
to the Spanish Group for the Study of Infections in Transplant
Patients (GESITRA), the incidence of TB is 20 times greater in
transplant patients than in the national population (50/100 000
inhabitants), even when preventive treatment with isoniazid is
administered to PPD-positive patients [6]. Where prophylaxis
cannot be performed, surveillance mycobacterial cultures are
useful for the early diagnosis of TB [7]. Most patients develop
TB during the first 9 months following transplant; however, in a
smaller number of cases, the disease does not develop until
2 years after transplant, or even longer. Although scattered or
extrapulmonary forms of TB are more frequent in transplant
patients than in the general population, most transplant patients
develop pulmonary forms. Of all the factors contributing to the
occurrence of infections in transplant recipients, the most
important is iatrogenic immunosuppression. It is well known
that corticosteroids inhibit the immune response, cellular
immunity and, to a lesser extent, antibody formation; in these
circumstances, reactivation of latent M. tuberculosis may lead to
spread of the disease [8].
Complications such as bronchocentric granulomatosis have
been reported in association with M. tuberculosis [9,10], but
there are no documented cases of BOOP caused by this agent.
There are apparently no previous reports of either (a) bronch-
iolitis obliterans associated with heart transplantation (i.e. with-
out heart–lung transplantation) or (b) bronchiolitis obliterans
associated with pulmonary TB in inmunocompromised
patients. There has, however, been one report of an im-
munocompetent patient suffering BOOP associated with
M. avium [7].
In lung, heart–lung and 10% of bone marrow transplant
patients, BOOP appears in association with acute graft rejec-
tion, in many cases involving cytomegalovirus disease [2,11–
14]. Nevertheless, it has not been reported in association with
rejection in heart transplant patients.
In conclusion, it is felt that BOOP may be a manifestation of
TB, which should therefore be included in the differential
diagnosis of infectious causes of BOOP, particularly in the
immunocompromised patient. Given that once corticosteroid
treatment is started the prognosis of BOOP is good, correct
diagnosis—generally requiring open lung biopsy—is essential.
Inappropriate treatment could lead to the systemic spread
of TB.
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Table 2 Major BOOP-related microorganisms
Organism
Mycoplasma pneumoniae
Streptococcus pneumoniae
Nocardia
Asteroides
Aspergillus fumigatus
Burkholderia cepacia
Cytomegalovirus
Mycobacterium avium
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